| 1 | 
            Abeta antagonizes alpha7 nAChR receptors; opposed by nicotine. | 
        
        
            | 2 | 
            Abeta blocks voltage-gated Na+ channels in GABA neurons causing abberant excitation | 
        
        
            | 3 | 
            Abeta causes selective neuronal mortality. This requires cell membrane binding. | 
        
        
            | 4 | 
            Abeta decreases apical dendrite arborizations in cortical pyramidal cells in transgenic mice | 
        
        
            | 5 | 
            Abeta decreases dedritic spine number and alters dendritic spine morpholology | 
        
        
            | 6 | 
            Abeta decreases dendritic spine density and motility, increases spine legth. Rolipram blocks these e | 
        
        
            | 7 | 
            Abeta decreases dendritic spine number, causes dysmorphic spine shapes | 
        
        
            | 8 | 
            Abeta decreases p-21 activated kinase and causes cofilin pathology | 
        
        
            | 9 | 
            Abeta inhibits late LTP in animal models of Alzheimers | 
        
        
            | 10 | 
            Abeta inhibits LTP both in soluble and fibrillar conformational states | 
        
        
            | 11 | 
            Abeta inhibits LTP through TNFalpha | 
        
        
            | 12 | 
            Abeta inhibits nicotinic ACh receptors at pre-synaptic glutamatergic terminals  | 
        
        
            | 13 | 
            Abeta inhibits PAK, stimulates ROCK and impairs synapses by TLR signaling | 
        
        
            | 14 | 
            Abeta modulates A current (HEK293 cells) | 
        
        
            | 15 | 
            Abeta oligomer causes aberrant activity of p-21 activated kinase | 
        
        
            | 16 | 
            Abeta oligomer inhibits p-21 activated kinase and stimulates ROCK signalling | 
        
        
            | 17 | 
            Abeta peptides block LTP in rat CA1 in vivo | 
        
        
            | 18 | 
            Abeta-derived diffusible ligands (ADDLs) attack synapses at or near NMDA receptors | 
        
        
            | 19 | 
            Abeta42/Abeta40 ratio correlates with impaired LTP in a mouse model of Alzheimers | 
        
        
            | 20 | 
            ACh Esterase inhibitors decrease Abeta production by influencing APP processing | 
        
        
            | 21 | 
            AD combined treatment with cholinesterase inhibitor and alpha-adrenergic agonist. | 
        
        
            | 22 | 
            Aging causes reduction in dendrite complexity, spine loss, decreased glutamate, increased GABA | 
        
        
            | 23 | 
            Aging decreases NMDA receptors and increases GABA A-receptor mediated inhibition | 
        
        
            | 24 | 
            Alpha4beta2 receptor blockade causes memory impairment | 
        
        
            | 25 | 
            AMPA receptor downscaling in AD | 
        
        
            | 26 | 
            Apolipoprotein E4 (Apo E4) levels are inversely correlated with dendritic spine density | 
        
        
            | 27 | 
            BACE1 required for LTP at mossy fiber-CA3 synapses | 
        
        
            | 28 | 
            beta Amyloid increases calcium currents | 
        
        
            | 29 | 
            beta Amyloid increases calcium currents (2) | 
        
        
            | 30 | 
            beta-Amyloid activates I_L by MAP Kinase | 
        
        
            | 31 | 
            Beta-amyloid blocks high frequency stimulation induced LTP but not nicotine enhanced LTP | 
        
        
            | 32 | 
            beta-Amyloid impairs LTP/LTD | 
        
        
            | 33 | 
            beta-Amyloid potentiates Ca influx through L-type Ca channels | 
        
        
            | 34 | 
            beta-amyloid reduces IA | 
        
        
            | 35 | 
            beta-Amyloid-induced depression of LTP attenuated by Verapamil | 
        
        
            | 36 | 
            Chronic nicotine decreases NGF and improves memory performance | 
        
        
            | 37 | 
            Donepezil modulates potassium channels | 
        
        
            | 38 | 
            Drebrin decrease in frontal cortex correlated with mild Alzheimer's disease | 
        
        
            | 39 | 
            Galantamine increases dopamine release in the hippocampus | 
        
        
            | 40 | 
            Ginkgolides protect against amyloid-beta1-42-mediated synapse damage in vitro. |